Skip to main content

Table 2 Changes of BASDAI, pain VAS scores, and Morning stiffness-VAS scores

From: Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels

 

wIRA group (n = 120)

Control group (n = 120)

Difference d

t-statistic

P value

95% CI

BASDAI

 Before T*

8.33 ± 0.71

8.36 ± 0.74

− 0.04 ± 0.35

− 0.632

0.531

− 0.15~0.08

 After T

7.65 ± 0.65

7.90 ± 0.62

− 0.26 ± 0.56

− 2.907

0.000

− 0.44~− 0.08

 Difference d

0.68 ± 0.46

0.45 ± 0.49

0.35 ± 0.50

 95% CI

0.53~0.83

0.30~0.61

0.24–0.47

P value

0.000

0.000

0.000

Pain VAS scores

 Before T

8.85 ± 0.48

8.82 ± 0.45

0.03 ± 0.34

0.605

0.549

− 0.08~0.14

 After T

7.30 ± 0.65

7.77 ± 0.46

− 0.46 ± 0.54

− 5.436

0.000

− 0.63~− 0.29

 Difference d

1.55 ± 0.49

1.05 ± 0.35

0.27 ± 0.48

 95% CI

1.39~1.70

0.94~1.16

0.16–0.37

P value

0.000

0.000

0.000

Morning stiffness VAS scores

 Before T

8.81 ± 0.46

8.75 ± 0.50

0.06 ± 0.37

1.071

0.291

− 0.06~0.18

 After T

7.26 ± 0.59

7.80 ± 0.55

− 0.54 ± 0.55

− 6.205

0.000

− 0.72~− 0.36

 Difference d

1.55 ± 0.50

0.95 ± 0.35

0.28 ± 0.50

 95% CI

1.38~1.71

0.83~1.06

0.17–0.39

P value

0.000

0.000

0.000

  1. T treatment, BASDAI bath ankylosing spondylitis disease activity index, VAS visual analogue scale, CI confidence interval
  2. *Before treatment: wIRA treatment (before the start of the first stage of treatment regimen A and before the start of the second stage of treatment regimen A); control group (before the start of the first stage of treatment regimen B and before the start of the second stage of treatment regimen A). After treatment: values before the corresponding treatment regimen and after the corresponding treatment regimen